Global Histone Deacetylase 6 Market Size By Type (Citarinostat, CKD-504), By Application (CNS Lymphoma, Colon Cancer), By Region, And Segment Forecasts, 2023 to 2032

The Global Histone Deacetylase 6 (HDAC6) Market was valued at USD 1.4 billion in 2023 and is expected to reach USD 3.9 billion by 2031, expanding at a compound annual growth rate (CAGR) of 13.7% during the forecast period from 2023 to 2031. The growth of this market is fueled by increasing research and development in oncology, rising investment in epigenetic drug discovery, and the emerging role of HDAC6 inhibitors in neurodegenerative and autoimmune disorders. HDAC6, a unique isoform within the histone deacetylase family, is increasingly being recognized for its cytoplasmic regulatory roles in cancer progression, protein degradation, and immune modulation.

Drivers:

1. Rising Investment in Oncology Research

The growing global burden of cancer has prompted substantial investments in novel therapeutic approaches. HDAC6 inhibitors, with their selective cytoplasmic activity and potential for fewer side effects, are gaining traction as adjunctive and standalone cancer therapies.

2. Advancements in Epigenetic Drug Development

Ongoing technological advancements and increased understanding of epigenetics are supporting the development of targeted therapies. HDAC6 inhibitors are at the forefront, especially for hematologic malignancies and solid tumors, due to their specificity and promising preclinical outcomes.

3. Increasing Prevalence of Neurodegenerative Diseases

HDAC6 plays a crucial role in neurodegenerative pathways, particularly in conditions like Alzheimer's and Parkinson’s disease. The potential of HDAC6 inhibitors to restore microtubule function and protein homeostasis makes them an attractive candidate for therapeutic development in CNS disorders.

Restraints:

1. High Development Costs and Regulatory Hurdles

The cost of clinical trials for HDAC6 inhibitors is high, with stringent regulatory pathways in place for approval. Additionally, due to their novel mechanism, comprehensive safety profiling is required, slowing down development timelines.

2. Limited Clinical Validation

Despite promising preclinical data, limited late-stage clinical trial evidence exists for HDAC6 inhibitors, posing a challenge for market expansion and widespread clinical adoption.

Opportunity:

1. Expansion in Autoimmune and Inflammatory Disease Research

Emerging studies suggest HDAC6’s involvement in immune regulation, opening up opportunities in diseases such as rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease.

2. Strategic Collaborations and Licensing Deals

Biopharmaceutical companies are increasingly entering into partnerships with academic institutions and startups to co-develop HDAC6-focused therapies, fast-tracking commercialization through shared resources and technologies.

Market by System Type Insights:

Based on system type, Selective HDAC6 Inhibitors dominated the market in 2023, driven by their targeted action, reduced toxicity, and increased effectiveness compared to pan-HDAC inhibitors. Molecules such as ricolinostat and citarinostat are progressing through clinical development with promising results. The Dual HDAC Inhibitors segment is also gaining momentum, particularly for combination therapies in resistant cancer types.

Market by End-use Insights:

By end-use, Pharmaceutical & Biotechnology Companies emerged as the largest contributors in 2023. These firms are actively involved in developing and commercializing HDAC6 inhibitors, leveraging advanced drug discovery platforms. Academic & Research Institutions also represent a significant segment, focusing on early-stage research and target validation studies that feed into the commercial pipeline.

Market by Regional Insights:

North America accounted for the largest share of the Global HDAC6 Market in 2023, backed by strong R&D infrastructure, substantial funding for epigenetic research, and the presence of leading pharmaceutical companies. Europe followed closely, driven by increasing collaboration between research institutes and biopharma firms. The Asia-Pacific region is projected to witness the fastest growth through 2031, propelled by rising healthcare expenditure, expanding clinical trial activity, and growing interest in precision medicine.

Competitive Scenario:

Prominent players in the Global HDAC6 Market include Acetylon Pharmaceuticals (a subsidiary of Celgene/Bristol-Myers Squibb), Reverie Labs, Vivace Therapeutics, Mirati Therapeutics, Sanofi, and Novartis AG. These companies are focused on developing HDAC6-specific drug candidates, entering strategic licensing deals, and exploring novel indications beyond oncology.

Recent Developments:

2023: Acetylon Pharmaceuticals presented Phase II data on citarinostat combined with immunomodulatory drugs for relapsed multiple myeloma.

2024: Reverie Labs announced preclinical success using AI-designed HDAC6 inhibitors for CNS applications.

2025: Sanofi initiated a multi-center Phase I trial evaluating the efficacy of its proprietary HDAC6 inhibitor in solid tumors.

Scope of Work – Global Histone Deacetylase 6 Market

Report Metric Details

Market Size (2023) USD 1.4 billion

Projected Market Size (2031) USD 3.9 billion

CAGR (2023–2031) 13.7%

Market Segments By System Type (Selective, Dual HDAC Inhibitors), By End-use, By Region

Growth Drivers Rise in oncology research, neurodegenerative disease focus, epigenetic R&D

Opportunities Expansion in autoimmune indications, strategic collaborations

Key Market Developments:

April 2023: Mirati Therapeutics expanded its HDAC6 pipeline into CNS disorders, signaling new therapeutic potential beyond oncology.

August 2024: Novartis entered into a licensing agreement with a biotech firm specializing in neuroinflammation pathways targeting HDAC6.

January 2025: Vivace Therapeutics announced the successful completion of preclinical studies on a new generation HDAC6 inhibitor with multi-target modulation.

FAQs:

1) What is the current market size of the Global Histone Deacetylase 6 Market?

The market size was USD 1.4 billion in 2023.

2) What is the major growth driver of the Global Histone Deacetylase 6 Market?

Major growth is driven by increased oncology research and advances in epigenetic drug development.

3) Which is the largest region during the forecast period in the Global Histone Deacetylase 6 Market?

North America is projected to remain the largest region throughout the forecast period.

4) Which segment accounted for the largest market share in the Global Histone Deacetylase 6 Market?

The Selective HDAC6 Inhibitors segment held the largest share in 2023.

5) Who are the key market players in the Global Histone Deacetylase 6 Market?

Key players include Acetylon Pharmaceuticals, Reverie Labs, Sanofi, Vivace Therapeutics, and Novartis AG.